Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.

Disease models & mechanisms - 1 Jul 2012

Anastasaki Corina, Rauen Katherine A, Patton E Elizabeth

Abstract excerpt

Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Ectodermal Dysplasia
Share to Embryo, Nonmammalian

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Facies

Share to Failure to Thrive

Share to Heart Defects, Congenital

Share to Mitogen-Activated Protein Kinase Kinases

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 22301711
DOI: 10.1242/dmm.008672
PMCID: PMC3380717

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.PMID 22301711Read ↗

Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.Semantic proximity Read ↗

New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.Semantic proximity Read ↗

The Cardiofaciocutaneous Syndrome: From Genetics to Prognostic–Therapeutic ImplicationsSemantic proximity Read ↗

Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.Semantic proximity Read ↗

Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?Semantic proximity Read ↗

Mek1Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome.Semantic proximity Read ↗

In vivo severity ranking of Ras pathway mutations associated with developmental disorders.Semantic proximity Read ↗

Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki SyndromeSemantic proximity Read ↗

Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.Semantic proximity Read ↗

MEK genomics in development and disease.Semantic proximity Read ↗

Divergent effects of intrinsically active MEK variants on developmental Ras signaling.Semantic proximity Read ↗

Ras/MAPK dysregulation in development causes a skeletal myopathy in an activating BrafL597V mouse model for cardio-facio-cutaneous syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.